PT - JOURNAL ARTICLE AU - Elgohary, Mohamed Abdel-Salam AU - Hasan, Eman Medhat AU - Ibrahim, Amany Ahmad AU - Ahmed Abdelsalam, Mohamed Farouk AU - Abdel-Rahman, Raafat Zaher AU - Zaki, Ashraf Ibrahim AU - Elaatar, Mohamed Bakr AU - Elnagar, Mohamed Thabet AU - Emam, Mohamed Emam AU - Hamada, Mahmoud Moustafa AU - Abdel-Hamid, Taimour Mohamed AU - Abdel-Hafez, Ahmad Samir AU - Seadawy, Mohamed G. AU - Fatoh, Ahmad Rashad AU - Elsaied, Mohamed Ali AU - Sakr, Marwa Abdel-Rahman AU - Elkady, Ahmed Omar AU - Shehata, Mohamed Muawad AU - Nawar, Osama Mohamed AU - Selem, Mohamed Abu-elnaga AU - Abd-aal, Mohamed Saeed AU - Lotfy, Hany Hafez AU - Elnagdy, Tarek Refaat AU - Helmy, Sherine AU - Mubark, Magdy Amin TI - Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial AID - 10.1101/2021.05.19.21257429 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.19.21257429 4099 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257429.short 4100 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257429.full AB - Background COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection..Methods This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings.Results Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to ICU (RR=1.17, P=0.776). There was no significant difference between treatment groups regarding Total Leukocyte Count, Neutrophils count, Lymph and Urea.Conclusion Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04530422Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee of Egyptian Centre for Research and Regenerative MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability from the Corresponding Author